Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Here’s a look at the top three companies from the “Top 20 Life Science Startups to Watch in 2018.”
The three-way deal is focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
State-of-the-art facility expands WuXi STA’s capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial
The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic
BioTek Announces the New Cytation 7 With Upright and Inverted Microscopes, Plus Multi-Mode Detection
The new Cytation™ 7 Cell Imaging Multi-Mode Reader from BioTek Instruments combines an automated upright microscope, an inverted microscope, and multi-mode microplate detection in a single instrument.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Pharma, biotech and life sciences companies boost their leadership ranks with this weeks Movers & Shakers.
“We are Earth’s Tech Support,” declared Randall Kirk, Executive Chairman of the Board of Directors and former CEO of Intrexon. His company is one of the biggest developers of synthetic biology (or engineering biology) applications in therapeutics, agriculture and chemicals.
The company is changing its name to Precigen, Inc. and tapped Helen Sabzevari as its new president and chief executive officer.